Epigenomics AG and Royal Philips Electronics have entered into a collaboration and licensing agreement focusing on novel technologies and methods targeted at the diagnosis of various cancers.

Under the agreement both parties will jointly perform feasibility studies aimed at developing an integrated and fully automated instrument platform for the diagnosis of certain cancers based on DNA methylation biomarkers.

In addition, Philips obtained the option to license the required technologies and biomarkers separately or in combination for diagnostic applications. The option may be exercised upon the successful completion of the feasibility studies. Financial details have not been disclosed.